Aim: The MinION nanopore sequencing device opens the opportunity to cost-effective and point-ofcare DNA sequencing. We developed a multiplex assay targeting pharmacogenetic variants related to clopidogrel and warfarin, two commonly used drugs that show response variability due to genetic polymorphisms. Materials & Methods: Six reference and 78 clinical DNA samples were amplified by PCR to generate 15 amplicons targeting key variants. These products were then barcoded to enable sample multiplexing. Three variant calling tools were used to compare genotyping accuracy. Results and Conclusions: All but three samples were successfully sequenced and genotyped. Nanopolish software achieved accuracy > 90 % for all except one variant. While minor mis-genotyping issues exist, this work demonstrates that drug-specific or broad pharmacogenetic screening assays are possible on the MinION sequencing device.
Introduction 1
Clopidogrel and warfarin are two commonly used drugs for anticoagulation, with high variability in 2 inter-individual responses. For both drugs, much of the variability is attributed to genetic factors, 3 with pharmacokinetic variation in patients taking clopidogrel being associated with variation in the 4 CYP2C19 gene [1] and warfarin with CYP2C9 and VKORC1 [2] . Both CYP2C19 and CYP2C9 are 5 polymorphic genes with more than 30 known alleles [1] . Moreover, recent publications suggest that 6 other genes are also associated with variable drug response, including B4GALT2 [3] and ABCB1 [4, 5] 7
for clopidogrel and GGCX [6] and CYP4F2 [6] for warfarin. 8
Various assays have been developed to screen clopidogrel and warfarin related variants including 9 point of care tests [7, 8] , that usually detect a subset of common variants. Extensive panels of 10 pharmacogenetic variants are available through technologies such as mass spectrometry or next 11 generation sequencing. These approaches, however, involve high capital cost and are not always 12 accessible by small-scale laboratories. 13
MinION (Oxford Nanopore Technologies (ONT), Oxford, UK) is a pocket-sized, portable sequencing 14 device, using the disruptive nanopore technology [9] . It contains an array of nano-scale protein pores 15 embedded in a membrane, across which a current is passed, and single stranded DNA or RNA can be 16 streamed through the pores and sequenced in real-time [10, 11] . The device offers the advantage of 17 portability and almost-zero capital cost, opening the opportunity for point-of-care sequencing, 18 particularly given recent release of smaller-scale, cheaper flow cells ("flongles", ONT). The main 19 factor limiting its wide utility is the relatively high error rate compared to other sequencing 20 technologies. However, the technology is evolving rapidly, with improvements in the device, 21 chemistries and bioinformatic tools, which are contributing to improvements in accuracy [12] . 22
As proof-of-principle for a potential point of care test, we developed a multiplex assay on this 23 technology, focusing on pharmacogenetic variants related to variability in clopidogrel and warfarin 24
response. The assay contained genetic variants reported as clinically relevant by the Clinical 25
Pharmacogenomics Implementation Consortium (CPIC) guidelines [13] , as well as covering new 26 variants reported in recent publications [3] [4] [5] [6] 15] (Table 1) . Use of a polymerase chain reaction (PCR) 27
barcoding approach enabled us to multiplex 84 samples in one sequencing run. 28
Materials and Methods

29
Samples 30
Five reference DNA samples (Coriell Institute, Camden, NJ, USA -see Supplementary Table 1 ) and one 31 in-house DNA sample with known genotypes were used as controls. Seventy eight samples from a 32 cohort of patients who had undergone percutaneous coronary intervention (PCI) [16] , with available 33 CYP2C19*2, CYP2C19*3, and CYP2C19*17 genotype data, were included to validate the assay. 34
Multiplex PCR 35
A 15-plex PCR, covering a total of 27 variants, was designed using MFE-primer3.0 36 (https://design.igenetech.com/) ( Table 1 ). Amplicon lengths varied between 163 -240 bps. The 37 forward and reverse primers were prepared separately to make 10 M of each pool. Wembley, Australia) was used for both the initial multiplex PCR and the barcoding PCR. 53
MinION library preparation 54
The barcoded samples were purified using HighPrep TM PCR magnetic beads (Magbio, Gaithersburg, 55 USA). Each barcoded sample was quantified with Qubit, normalized in concentration and pooled in 56 equimolar amounts. Eighty ng of the pooled DNA was used in the MinION library preparation, 57
according to the 1D PCR Barcoding (96) amplicons (SQK-LSK108) protocol (ONT). 58
Data analysis 59
The MinION sequencing was run for 48 hours as per protocol using an R9 flowcell. The fast5 files 60 generated were basecalled and demultiplexed using Albacore version v2.3.0 (ONT), resulting in a 61 fastq file for each barcode. The fastq files were aligned to a custom reference sequence which was 62 built from human hg19 reference sequences of each amplicon in a fasta file (Supplementary file) 63 using BWA MEM. Three different variant calling tools, marginCaller from marginAlign [17] , 64 nanopolish [18] , and VarScan 2 [19] were used to call variants. NanoOK [20] , Minion-QC [21] and 65
Qualimap [22] were used to generate quality control parameters including read errors, read depth, 66
and percentage of reads alignment. Integrative Genomics Viewer (IGV, Broad Institute, Boston, 67 MA) [23] was used to visualise alignment files. Read depth plot was generated using ggplot2 in R 68 (Vienna, Austria). 69
Sanger sequencing 70
A nested PCR using 0.5 M of sequence-specific primers was performed in a 20 L reaction containing Terminator in 10 L reaction. Dye incorporation was performed in a thermal cycler with 25 cycles of 76 96 °C for 10 seconds, 50 °C for 5 seconds, and 60 °C for 4 minutes, and subsequently purified using 77 Sephadex G-50 before being sequenced using the AB3130xL genetic analyzer (Thermo Fisher 78 Scientific). 79
Results
80
Read characteristics 81
One sequencing run containing 84 barcoded samples produced 0.9 million reads, of which one third 82 passed the Albacore default quality threshold qscore of seven. These reads were then used for further 83 downstream analysis. The majority of the passed reads (94.6 %) mapped to the reference sequence. 84
The average error rate was 2.94%, 3.83%, and 3.82% for insertion, deletion, and substitution errors, 85 respectively. 86
The average read depth of each amplicon varied significantly between 43 and 985x 87 (F(14,1200)=146.6, p<0.001). Variability was also significantly different among amplicons (Levene's 88 test P < 0.001) ( Figure 1 ). Three amplicons, ABCB1, CYP2C96 and VKORC1rs7294 showed very high 89 read depth, while four amplicons, CYP2C192, CYP2C1917, CYP2C194, and CYP2C93 showed 90 relatively low read depth of < 100 across all samples. Three out of the 78 clinical samples were 91 excluded from analysis due to low yield in initial PCR and low read depth across all amplicons, with 92 less than 50 % of reads being mapped to the reference sequence. Twelve samples for B4GALT2, two 93 samples for CYP2C194, one sample for CYP2C93, and four samples for CYP4F2 amplicons had very 94 low read depth (<10), and were also excluded from analysis (Supplementary Table 1 ). 95 For three genotypes (CYP2C19*2, CYP2C19*3, and CYP2C19*17), data from two orthogonal assay 99 platforms (Nanosphere Verigene ® or Sequenom MassARRAY platform) were available [16] , and 100 initial comparative analysis was done on these three genotypes. Accuracy for CYP2C19*3 genotyping 101 was 100 % across all variant calling tools (Figure 2) , with the three heterozygote samples for 102 CYP2C19*3 being accurately detected using the MinION assay. fraction of total reads that support the alternate allele for this sample was close to 1 (0.78), indicating 111 a homozygote variant. Moreover, the read depth was > 100, however nanopolish incorrectly called 112 this sample as heterozygote. 113
Other variants 114
Analysis of the other variants included in this assay was first done on control samples. Nanopolish 115 resulted in 100% accuracy on control samples while marginCaller missed the CYP2C9*6 variant in 116 one sample and VarScan 2 missed a total of 11 variants in six control samples ( Supplementary Table  117 1). As nanopolish gave the best accuracy compared to the other two variant calling tools, it was used 118
to analyze other variants across all samples. Many of the variants included in our custom designed 119 assay are rare, and there were only eight variants which were detected in at least three of the 81 120 samples. We performed Sanger sequencing for the eight variants for randomly selected subsets of 121 the samples. Accuracy of genotype data from MinION sequencing compared with Sanger sequencing 122 is shown in Table 2 . 123
Insert Table 2 here 124 Two heterozygote samples for CYP2C9*3 were called as wild-type by nanopolish. These two samples 125 were of relatively low read depth (< 30). The discordant samples for B4GALT2, VKORC1 rs9923231, 126
and VKORC1 rs7294 variants consisted of homozygote samples which were mis-called as 127
heterozygotes. This inaccuracy could not be explained by read depth, as some of these samples had 128 a read depth > 100. Genotype data for all samples is available in Supplementary Table 1 . 129
The discordant results for VKORC1 rs9923231 could be resolved by analyzing the BAM files. As seen 130
in Figure 3 The MinION on the other hand is a portable sequencing tool, available to any laboratory scale and has 149 been use in field settings as far as outer space [18, 25, 26] . 150
We have described an assay detecting multiple genetic variants known to affect response to 151 clopidogrel and/or warfarin therapy. This assay can easily be modified by designing new sets of 152 primers. The capability of multiplexing up to 96 samples in one sequencing run resulted in a 153 reasonably cost-effective approach to genotyping. Cost-effectiveness might further be improved with 154 the smaller-scale, cheaper "Flongle" flow cells recently released by ONT. 155
The simple workflow of only one PCR reaction per sample was achieved by designing short 156 amplicons, which were previously shown to be compatible with the MinION [27] . All contigs were 157 amplified successfully, and despite the uneven yield among amplicons, the majority of genotypes 158 could be accurately determined using appropriate bioinformatics tools. Genotyping accuracy was in 159 part dependent on the variant calling tool. We showed that nanopolish achieved the best accuracy 160 compared with marginCaller and VarScan 2. Instead of calling variants as single bases, nanopolish 161 investigates a block of 10 bases at a time, and calculates the best likely haplotype using a hidden 162
Markov model [18] . Nanopolish could detect both single base substitutions and a single base deletion. 163
Although generally accurate, a small proportion of incorrect genotype calls were observed. The 164 majority of these were homozygote variants miscalled as heterozygotes. As previously reported, this 165 seems to be a MinION and/or nanopolish specific problem [10] . Using nanopolish to genotype a 166 fraction of variants on chromosome 20, the authors reported that 3,217 out of 4,781 mislabelled 167 variants were due to this kind of error [10] . Improvements to variant calling tools for nanopore 168 sequencing data may lead to more accurate calling. 169
Accuracy in MinION sequencing is also sequence-dependent [28] . This was well reflected in this assay 170 with some genotypes showing better accuracy than the others. In particular, CYP2C19*3 showed 171 perfect accuracy regardless of the bioinformatic tools used to genotype. VKORC1 rs9923231, on the 172 contrary, showed the least accurate genotyping despite the relatively high read depth (> 100). 173
However, these errors could be resolved by visual inspection of the alignment (BAM) file. tool is important, with nanopolish performing best for the assay described here. However, some mis-179 genotyping issues remain, which need to be resolved before such assays could be applied in a clinical 180 or diagnostic setting. Continual improvements in chemistry and flowcells by ONT, and continuing 181 development of bioinformatic tools by the research community is likely to resolve these issues in the 182 future. 183 
